Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent.
Cerebrolysin (Cere) is a compound with neurotrophic activity. It has been shown to be effective in the treatment of Alzheimer's disease (AD) in earlier trials. In this multicenter, randomized, double-blind, placebo-controlled, parallel-group study, patients were injected intravenously with placebo or 30 mL Cere five days per week for four weeks. Effects on cognition and global function were evaluated with the Alzheimer Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and the Clinicians Interview-based Impression of Change with Caregiver Input scale (CIBIC+) 4, 12, 24 weeks after the beginning of the injections. 192 patients were enrolled, 95 were randomized to placebo, and 97 to Cere. At baseline, there was a significant difference between groups for age, age of onset of dementia, and the number of patients with hallucinations. At week 12 there was a significant difference on the CIBIC+ (p = 0.033) in favor of Cere. The number of CIBIC+ responders (score < or = 4), was significantly higher (p = 0.007), with 68 (76%) in the Cere group and 51 (57%) in the placebo group. Trends were noted in the Disability Assessment in Dementia scale and the Cornell Depression Scale. Adverse events were recorded in 73% of placebo and 64% of Cere patients. Most common adverse events were headaches, dizziness, weight loss and anxiety.


CONCLUSIONS
Cere treatment was well tolerated and resulted in significant improvements in the global score two months after the end of active treatment.
McGill Centre for Studies in Ageing, Montreal, Quebec, Canada.
M
M
Panisset
S
S
Gauthier
H
H
Moessler
M
M
Windisch
D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000235:genetics / Q000523:psychology; D000596:Amino Acids / Q000009:adverse effects / Q000627:therapeutic use*; D001057:Apolipoproteins E / Q000235:genetics; D003071:Cognition / Q000187:drug effects; D003863:Depression / Q000209:etiology / Q000523:psychology; D004185:Disability Evaluation; D004311:Double-Blind Method; D005260:Female; D005787:Gene Frequency; D006579:Heterozygote; D006801:Humans; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D010641:Phenotype; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D016896:Treatment Outcome
D000596:Amino Acids; D001057:Apolipoproteins E; D018696:Neuroprotective Agents; D010919:Placebos; C006952:cerebrolysin